Skip to content
Triangle logo TriangleGet started
← Study library

NCT00481871 · REGISTRY CONDITION SEARCH

Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE1, PHASE2
Status at capture
COMPLETED
Registry last update
2020-01-07

This study is for patients with lymphoproliferative malignancies that have progressed after receiving a previous treatment (relapsed) or are no longer responding to treatment (refractory). To be in this study, patients must have certain types of Hodgkin's lymphoma (HL), peripheral T-cell lymphoma (PTCL), or B-cell lymphoma, including Waldenstrom's macroglobulinemia. This study is being done to find doses of the combination of pralatrexate and gemcitabine with vitamin B12 and folic acid that can be safely given to patients with these types of lymphoma and explore the effectiveness of the treatment.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Objective Responses Assessed by International Workshop Criteria (IWC)

→

outcome · POSTED

Duration of Response

→

outcome · POSTED

Progression-free Survival (PFS) Time

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Phase 1: Histologically/cytologically confirmed lymphoproliferative malignancy. Patients with Hodgkin lymphoma (HL) or non-HL are eligible, with exceptions per exclusion criteria. * Phase 2a: Histologically/cytologically confirmed HL, peripheral T-cell lymphoma (PTCL), or B-cell lymphoma including Waldenström's macroglobulinemia, with exceptions per exclusion criteria. * Progression of disease (PD) after at least 1 prior treatment (any number of prior therapies allowed). PD after last prior treatment and recovered from toxic effects of prior therapy. Patients treated with an FDA-approved monoclonal antibody therapy may be enrolled at any time after the therapy if they have PD. * PTCL patients must have received single-agent pralatrexate as a prior therapy. * Eastern Cooperative Oncology Group performance status ≤ 2. * Adequate blood, liver and kidney function per laboratory tests. * Has taken 1 mg daily oral folic acid for at least 7 days prior to planned start of pralatrexate and received 1 mg vitamin B12 intramuscularly within 10 weeks of the planned start of pralatrexate. * Females of childbearing potential must practice a medically acceptable contraceptive regimen from first dose until at least 30 days after last dose of pralatrexate and have a negative serum pregnancy test within 14 days prior to the first day of study treatment. Postmenopausal (defined as greater than 12 months since last menses) and surgically sterilized females do not require this test. * Males who are not surgically sterile must practice a medically acceptable contraceptive regimen from first dose until at least 90 days after last dose of pralatrexate. * Give written informed consent. Exclusion Criteria: * Phase 1 1\. B-cell: lymphoplasmacytic lymphoma (± Waldenström's macroglobulinemia); plasma cell myeloma/plasmacytoma; hairy cell leukemia. * Phase 2a 1. PTCL: precursor T/Natural Killer (NK) neoplasms, with the exception of blastic NK lymphoma; T-cell prolymphocytic leukemia; T-cell large granular lymphocytic leukemia; mycosis fungoides (MF), except transformed MF; Sézary syndrome; primary cutaneous CD30+ disorders: Anaplastic large cell lymphoma and lymphomatoid papulosis. 2. B-cell: plasma cell myeloma/plasmacytoma; hairy cell leukemia. * Relapsed HL or diffuse large B-cell lymphoma patients who are candidates for high dose therapy and autologous stem cell transplantation (SCT) and for whom it is a standard curative option. * Active concurrent malignancy (except non melanoma skin cancer or carcinoma in situ of the cervix). If there is a history of prior malignancy, must be disease free for at least 5 years. * Congestive heart failure Class III/IV. * Uncontrolled hypertension. * Human immunodeficiency virus (HIV)- positive diagnosis with CD4 less than 100 or detectable viral load within past 3 months and receiving anti-retroviral therapy. * Hepatitis B or C virus with detectable viral load or immunological evidence of chronic active disease or receiving/requiring antiviral therapy. * Central nervous system disease. * Undergone an allogeneic SCT. * Patients with disease refractory to peripheral blood SCT, or who have relapsed less than 100 days since an autologous or peripheral blood SCT. * Active uncontrolled infection, underlying medical condition including unstable heart disease, or other serious illness impairing the ability to receive protocol treatment. * Major surgery within 2 weeks of planned start of treatment. * Receipt of any conventional chemotherapy or radiation therapy (encompassing greater than 10% of bone marrow) within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to study treatment or planned use during the study. * Receipt of systemic corticosteroids within 7 days of study treatment, unless on a continuous dose of no more than 10 mg/day of prednisone for at least 1 month. * Use of investigational drugs, biologics, or devices within 4 weeks prior to study treatment or planned use during the study. * Received a monoclonal antibody within 3 months without evidence of PD. * Previous exposure to pralatrexate and/or gemcitabine if discontinued due to treatment-related toxicity.
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. intervention Names
    1. Drug: Pralatrexate Injection
    2. Drug: Gemcitabine Hydrochloride
    3. Dietary Supplement: Vitamin B12
    4. Dietary Supplement: Folic Acid
    label
    Pralatrexate & Gemcitabine - Sequential Days
    type
    EXPERIMENTAL
  2. intervention Names
    1. Drug: Pralatrexate Injection
    2. Drug: Gemcitabine Hydrochloride
    3. Dietary Supplement: Vitamin B12
    4. Dietary Supplement: Folic Acid
    label
    Pralatrexate & Gemcitabine - Same Day
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Pralatrexate & Gemcitabine - Same Day
    2. Pralatrexate & Gemcitabine - Sequential Days
    description
    Intravenous (IV) push administration over 30 seconds to 5 minutes into a patent IV line containing normal saline (0.9% sodium chloride). Sequential Dosing: 10 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met. Same Day Dosing: 15 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met.
    name
    Pralatrexate Injection
    other Names
    1. FOLOTYN
    2. PDX
    3. Pralatrexate
    4. (RS)-10-propargyl-10-deazaaminopterin
    type
    DRUG
  2. arm Group Labels
    1. Pralatrexate & Gemcitabine - Same Day
    2. Pralatrexate & Gemcitabine - Sequential Days
    description
    Gemcitabine will be prepared and administered as an IV infusion as per manufacturer instructions. Sequential Dosing: 400 mg/m2 every 2 weeks (days 2 and 16) of a 4-week cycle until criteria for discontinuation per the protocol are met. Same Day Dosing: 600 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met.
    name
    Gemcitabine Hydrochloride
    other Names
    1. Gemcitabine
    2. Gemzar®, Eli Lilly and Company
    3. Gemcitabine Hydrochloride (HCl) for Injection
    type
    DRUG
  3. arm Group Labels
    1. Pralatrexate & Gemcitabine - Same Day
    2. Pralatrexate & Gemcitabine - Sequential Days
    description
    1 mg intramuscular injection Administered within 10 weeks of enrollment, every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate.
    name
    Vitamin B12
    other Names
    1. Cyanocobalamin
    type
    DIETARY_SUPPLEMENT
  4. arm Group Labels
    1. Pralatrexate & Gemcitabine - Same Day
    2. Pralatrexate & Gemcitabine - Sequential Days
    description
    1 mg orally Administered daily for at least 7 days prior to start of pralatrexate, throughout the study and for at least 30 days after last dose of pralatrexate.
    name
    Folic Acid
    other Names
    1. Vitamin B9
    2. Folate
    3. Folacin
    type
    DIETARY_SUPPLEMENT
Study design
allocation
RANDOMIZED
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
119
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Number of participants who achieved an objective response. Objective response was defined as a tumor response assessment of either complete response (CR) or partial response (PR) and was determined only for patients with measurable disease at baseline. A tumor response assessment reported by IWC without PET was used for any analyses in cases where an IWC+PET evaluation was not done.
    measure
    Objective Responses Assessed by International Workshop Criteria (IWC)
    time Frame
    Assessed every 8 weeks (+/- 1 week) for Phase II and no less than every 3 cycles for Phase I
secondary Outcomes
  1. description
    Duration of response was defined as the number of days between the date of first tumor response assessment of objective response to the time of the first tumor response assessment of progressive disease (PD) or death due to any cause (date of first PD assessment or death - date of first objective response assessment + 1)
    measure
    Duration of Response
    time Frame
    Response assessments were performed no less than every 3 cycles in the Phase 1 part of the study and every 8 weeks (± 1 week) in the Phase 2a part of the study
  2. description
    PFS time was calculated as the number of days from study day 1 to the date of PD or death, regardless of cause (date of PD or death - study day 1 + 1).
    measure
    Progression-free Survival (PFS) Time
    time Frame
    Response assessments were performed no less than every 3 cycles in the Phase 1 part of the study and every 8 weeks (± 1 week) in the Phase 2a part of the study
Full study description
brief Summary
This study is for patients with lymphoproliferative malignancies that have progressed after receiving a previous treatment (relapsed) or are no longer responding to treatment (refractory). To be in this study, patients must have certain types of Hodgkin's lymphoma (HL), peripheral T-cell lymphoma (PTCL), or B-cell lymphoma, including Waldenstrom's macroglobulinemia. This study is being done to find doses of the combination of pralatrexate and gemcitabine with vitamin B12 and folic acid that can be safely given to patients with these types of lymphoma and explore the effectiveness of the treatment.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-3c5e154da7dff28243a2
      requested nct id
      NCT00481871
      primary nct id
      NCT00481871
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      e270600534699a676fe83226e7a7b0f73aeb00c1d0a05cfc115c748864ad8173
      payload sha256
      0f308f4277abc4ab301e17c4d2391ae04346a0ed6e5dc06fdc798f38411fbfab
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-3c5e154da7dff28243a2
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00481871
      occurrences
      1. context exact
        NCT00481871
        end
        11
        exact text
        NCT00481871
        start
        0
      offset unit
      unicode_code_points
      query cond
      Peripheral T-Cell Non-Hodgkin Lymphoma
      query disease state id
      ds-peripheral-t-cell-non-hodgkin-lymphoma
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-peripheral-t-cell-non-hodgkin-lymphoma-000.json
      source file sha256
      e270600534699a676fe83226e7a7b0f73aeb00c1d0a05cfc115c748864ad8173
      source json pointer
      /studies/46/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      382421eec53256d9363285e56bd808db8e9e7ed4341fb6f2a5d3a47f68badfc5
    2. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-3e77622f762d1fa1c327
      requested nct id
      NCT00481871
      primary nct id
      NCT00481871
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      3234f0861d2ced54e8ead4ded6d0b985572d200cdbda2a8311b218b4b286bc5d
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-3e77622f762d1fa1c327
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00481871
      occurrences
      1. context exact
        NCT00481871
        end
        11
        exact text
        NCT00481871
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/385/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      382421eec53256d9363285e56bd808db8e9e7ed4341fb6f2a5d3a47f68badfc5

    Preserved source evidence · Not medical advice